UK Cancer Pain Management Market Analysis Report [2022-30] I Insights10

UK Cancer Pain Management Market Analysis

$ 3999

The UK Cancer Pain Management market is projected to grow from $169.52 Mn in 2022 to $219.8 Mn by 2030, registering a CAGR of 3.3% during the forecast period of 2022 - 2030. The main factors driving the growth would be the aging population, the rise in cancer diagnoses, and greater access to cancer screening and early detection techniques. The market is segmented by drug type and by disease. Some of the major players include Napp Pharmaceuticals (GBR), GW Pharmaceuticals (GBR), Grunenthal Pharma, Hisamitsu Pharmaceutical, Pfizer, and Teva Pharmaceuticals.

ID: IN10GBHS002 CATEGORY: Healthcare Services GEOGRAPHY: UK AUTHOR: Neha Davda

Buy Now

UK Cancer Pain Management Market Executive Summary

The UK Cancer Pain Management market is projected to grow from $169.52 Mn in 2022 to $219.8 Mn by 2030, registering a CAGR of 3.3% during the forecast period of 2022 - 2030. In the UK, the current health expenditure in 2020 was $4,682.21 per capita. This spending increased from 9.9% of GDP in 2019 to 12.0% of GDP in 2020. In 2020, the government-funded around 83% of all healthcare spending, or $ 260.2 Bn, a rise of 14.9% in real terms.

Cancer pain can be caused by the disease itself or by treatments like chemotherapy and surgery that are associated with it. The type, location, and degree of the pain determine what medications are used and how they are administered. A wide range of drugs is used to manage cancer pain. Acetaminophen and NSAIDs, which are non-opioids, are more usually used to treat mild to moderate cancer pain, whereas strong opioids, for instance, are more frequently used to treat severe pain. One of the long-standing participants in the global market for cancer pain management, Europe is also home to some of the top pharmaceutical companies active in the development of novel painkillers.

UK cancer pain management market analysis

Market Dynamics

Market Growth Drivers

A number of reasons, such as an aging population and a rise in cancer diagnoses, are likely to contribute to the growth of the cancer pain management market in the UK. The number of people with cancer, which frequently results in chronic pain, is rising in the UK as a result of the country's aging population. This is increasing the need for therapies and treatments for pain control. Additionally, more cancer diagnoses as a result of greater access to cancer screening and early detection techniques have fueled the expansion of the cancer pain management industry.

Market Restraints

The market for cancer pain management may be constrained in the UK by a number of issues, including restricted access to specialized pain management services, a lack of awareness, and competition from complementary and alternative therapies. These elements might limit access to care for people with cancer-related pain and hinder the expansion of the UK market for cancer pain management.

Competitive Landscape

Key Players

Napp Pharmaceuticals (GBR)
GW Pharmaceuticals (GBR)
Grunenthal Pharma
Hisamitsu Pharmaceutical
Pfizer
Teva Pharmaceuticals

Notable Recent Deals

December 2021: Hisamitsu Pharmaceutical and RaQualia Pharma entered into a license agreement for a novel sodium channel blocker. Prior to going to the clinical stage, Hisamitsu Pharmaceutical will perform preclinical research on new pain treatment drug(s) containing the molecule using its expertise in manufacturing transdermal pharmaceuticals. The development, manufacture, and marketing of the substance will be provided to Hisamitsu Pharmaceutical as the only worldwide rights under the licensing agreement.

Healthcare Policies and Regulatory Landscape

Several agencies, including the National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA), and the General Medical Council, regulate the healthcare system and the market for cancer pain treatment in the United Kingdom (GMC). These organizations are in charge of examining and policing cancer pain management therapies, drugs, and procedures. While the MHRA is in charge of ensuring the safety and effectiveness of medications used in pain management, NICE offers advice and recommendations on the use of medicines and therapies for cancer-related pain. The GMC offers recommendations for treating patients with pain in accordance with ethical and professional standards of care.

Reimbursement Scenario

The National Health Service (NHS) and its funding and reimbursement regulations for medical treatments and procedures regulate the reimbursement landscape for the pain management market in the United Kingdom. The NHS offers access to a variety of pain management therapies and treatments, though some of them may not be available due to financial or reimbursement limitations. Patients may occasionally need to find alternate sources of funding or pay out of pocket for specific medicines and treatments. Decisions on reimbursement are made based on a number of variables, such as the accessibility of treatments and therapies, their clinical efficacy, and their economic viability.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.